Drug-resistant TB is a major global public health problem that threatens the significant progress made in TB care and prevention in recent decades.
In most cases, tuberculosis is treatable and curable. However, standard TB treatment requires up to six months of drugs that can cause nausea, vomiting and stomach pain. The duration and side effects drive some people to abandon their treatment, which can lead to drug resistance -when tuberculosis bacteria is resistant to at least one of the main TB drugs.
Globally, only half of multidrugresistant tuberculosis (MDR-TB) patients who initiate treatment are successfully treated, mostly due to high mortality and falling out of the treatment programs. Outcomes for individuals with extensively drugresistant tuberculosis (XDR-TB) are worse -as reported by WHO in 2017, only 30 percent of patients were successfully treated.
As antimicrobial resistance goes, tuberculosis is an enormous problem.
Deaths from drug-resistant TB now account for about one-third of all antimicrobial resistance deaths worldwide. Treating drug-resistant TB is costlier and can take three to four times as long -not all people survive. 
Stronger Systems for Health
In the end, the response to drugresistant TB relies heavily on strong and functional health systems. One-quarter of the Global Fund's investments support building resilient and sustainable systems for health, including training for health workers, improved facilities and access, and strengthened information systems and supply chain management.
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About the Global Fund
The Global Fund is a 21st-century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. As a partnership between governments, civil society, the private sector and people affected by the diseases, the Global Fund mobilizes and invests nearly US$4 billion a year to support programs run by local experts in more than 100 countries. By challenging barriers and embracing innovative approaches, we are working together to better serve people affected by the diseases.
In Zaatari camp in the Jordanian desert, the Global Fund is supporting the provision of essential TB prevention, diagnosis and treatment services to Syrian refugees. What started as a temporary shelter for people fleeing the conflict in Syria has grown into a city of about 80,000 people. The people here benefit from TB services such as screening upon arrival, medical care and referral services, as well as health education.
